MannKind VP Juergen Martens Sells 1,458 Shares (MNKD)
MannKind (NASDAQ:MNKD) VP Juergen Martens sold 1,458 shares of the stock on the open market in a transaction dated Friday, June 20th. The shares were sold at an average price of $10.34, for a total value of $15,075.72. Following the completion of the transaction, the vice president now directly owns 114,024 shares of the company’s stock, valued at approximately $1,179,008. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
MNKD has been the subject of a number of recent research reports. Analysts at RBC Capital initiated coverage on shares of MannKind in a research note on Thursday, June 12th. They set an “outperform” rating and a $16.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of MannKind in a research note on Wednesday, May 14th. They now have a $7.00 price target on the stock. Finally, analysts at Piper Jaffray upgraded shares of MannKind from an “underweight” rating to a “neutral” rating in a research note on Wednesday, May 14th. They now have a $6.50 price target on the stock, up previously from $2.00. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $8.79.
MannKind (NASDAQ:MNKD) opened at 10.73 on Tuesday. MannKind has a 52 week low of $3.80 and a 52 week high of $11.11. The stock has a 50-day moving average of $8.62 and a 200-day moving average of $6.48. The company’s market cap is $4.055 billion.
MannKind (NASDAQ:MNKD) last released its earnings data on Monday, May 12th. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.13) by $0.01. During the same quarter in the prior year, the company posted ($0.15) earnings per share. Analysts expect that MannKind will post $-0.37 EPS for the current fiscal year.
MannKind Corporation (NASDAQ:MNKD) is a development-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.